It is currently Fri Apr 25, 2014 2:03 am

News News of Tysabri (Antegren or Natalizumab)

Site map of Tysabri (Antegren or Natalizumab) » Forum : Tysabri (Antegren or Natalizumab)

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

MSRC Tysabri Diary Updates

Kirsty has sent in her 18th & 19th Tysabri infusion updates.

You can read her new diary entries at http://bit.ly/u3SoFn

Jill has kindly sent in her last and final Tysabri diary entry, as she is switching to Gilenya due to JC Virus results.

We would like to thank Jill for all her Tysabri diaries and wish her good luck with Gilenya.

You can read Jill's final diary entry at ...
Read more : MSRC Tysabri Diary Updates | Views : 2311 | Replies : 11


Tysabri trial to evaluate use in secondary progressive MS

Image

Biogen Idec and Elan Corporation announced a global Phase 3b study that is being conducted to evaluate the effectiveness of Tysabri as a treatment for secondary-progressive multiple sclerosis (SPMS).

The Ascend study is part of an ongoing commitment of both Biogen Idec and Elan to find ways to improve the well-being of patients with multiple sclerosis. Ascend (A Study to Characterize the Efficacy of Natalizumab on Disability in SPMS) is a double-blind, placebo-controlled study ...
Read more : Tysabri trial to evaluate use in secondary progressive MS | Views : 1296 | Replies : 1


CYT107 gets orphan drug status in Europe - treatment of PML

Image

Cytheris SA, a privately held clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases, announced that the European Commission has granted an orphan designation for Cytheris' CYT017, glycosylated recombinant human interleukin-7 (glycosylated r-h-IL7), for the treatment of Progressive Multifocal Leukoencephalopathy (PML).

Additionally, Cytheris obtained scientific advice for a phase IIb study protocol with CYT107 in HIV-related PML. Cytheris has reached an agreement with the EMA on the key study endpoints. Cytheris will start this ...
Read more : CYT107 gets orphan drug status in Europe - treatment of PML | Views : 937 | Replies : 0


Who is the best candidate for Tysabri treatment?

I am new to this forum and looking for answers regarding Tysabri.

I was dx'd w/ r/r MS 11 years ago. Once I got consistent on Rebif, I have not had any relapses in more then 5 years. (I used to average about 4/year.) I have little issues pop up here and there, but nothing too concerning. My biggest issue is fatigue. I get a yearly checkup from my doctor. My MRI's are always clear. ...
Read more : Who is the best candidate for Tysabri treatment? | Views : 1521 | Replies : 1


Tysabri interruption results in disease activity return

Natalizumab interruption results in a high rate of MRI and clinical MS disease activity recurrence

Image

After a 24-week cessation of natalizumab treatment, a high rate of magnetic resonance imaging (MRI) and clinical disease activity recurs in patients with multiple sclerosis (MS) according to new research.

Natalizumab treatment duration has been associated with the development of progressive multifocal leukoencephalopathy (PML), a rare but often lethal and untreatable disorder of the central nervous system, characterized by ...
Read more : Tysabri interruption results in disease activity return | Views : 1699 | Replies : 5


7th infusion

7th infusion of natalizumab or tysabri been diagnosed for 9 months now, was a real shock at the time, i lost all power to my arms and lower limbs, my sight and had severely chronic memory loss, was quite scary as a teenager been told i had MS my future was planned before that day i wanted to be a nurse and travel but when i was told i could be in a wheelchair for ...
Read more : 7th infusion | Views : 1411 | Replies : 1


242 PML cases and 52 deaths - May 2012

Biogen Idec confirmed 10 new cases of PML (0505 2012). The total number of PML cases among the Tysabri users rises to 242 and the total number of deaths increased at 52 (three other patients died of PML). PML patients mortality is currently about 21 percent.
Read more : 242 PML cases and 52 deaths - May 2012 | Views : 4818 | Replies : 9


Health Canada approves updates to Tysabri product monograph

Health Canada approves updates to Tysabri product monograph to include anti-JC virus antibody status

Image

Health Canada has approved a product monograph change for Tysabri® that will help enable individual benefit risk assessment for patients with multiple sclerosis (MS). The new label identifies anti-JC virus (JCV) antibody status as a risk factor for developing an uncommon, but serious, brain infection known as progressive multifocal leukoencephalopathy (PML). This marks the third risk factor identified to help ...
Read more : Health Canada approves updates to Tysabri product monograph | Views : 1127 | Replies : 2


MS drug Tysabri leukoencephalopathy risk factors identified

Image


Multiple sclerosis patients taking natalizumab are at higher risk of developing progressive multifocal leukoencephalopathy (PML) if they are positive for the anti-JC virus antibodies, have been treated with immunosuppressants, and have been treated with natalizumab for longer periods, according to a study published in the May 17 issue of the New England Journal of Medicine.

Gary Bloomgren, M.D., and colleagues from Biogen Idec in Weston, Mass., estimated the risk of PML based on the ...
Read more : MS drug Tysabri leukoencephalopathy risk factors identified | Views : 1392 | Replies : 0


Would like to hear about teenagers' experiences with Tysabri

Hi, I'm new to this forum, and I live in Toronto, Ontario, Canada.

My 14-year old daughter was diagnosed with RRMS one year ago, and we are almost at the end of our ropes! She has been hospitilized at least 8 times in one year because the MS is extremely active. She seems to get relapse after relapse after relapse and only short periods of remission. She has been on Copaxone, steroids, IVIG, Cyclophosphamide and ...
Read more : Would like to hear about teenagers' experiences with Tysabri | Views : 1183 | Replies : 2


 

Login  •  Register


Statistics

Total posts 216695 • Total topics 22136 • Total members 13920